Boston Scientific Receives FDA Clearance, CE Mark Approval for Direxion Torqueable Microcatheter

Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation BSX has received U.S. Food and Drug Administration clearance and CE Mark approval for its Direxion™ Torqueable Microcatheter. Peripheral embolization is a technique used primarily by interventional radiologists to treat liver cancer, uterine fibroids and other challenging conditions.  It involves deliberately blocking a blood vessel to prevent blood flow to an area of the body, which can effectively shrink a tumor or block an aneurysm. "The Direxion Microcatheter's unique handling characteristics are intended to enable physicians to efficiently access difficult to navigate vessels across many types of peripheral embolization procedures," said Riad Salem, M.D., MBA, professor of Radiology and director of Interventional Oncology at Northwestern Memorial Hospital.  "Combined with a range of tip shape offerings and selection of pre-loaded systems, the Direxion Microcatheter offers an attractive portfolio that opens up a whole new dimension in microcatheter technology," said Robert Lewandowski, M.D., associate professor of Radiology at Northwestern Memorial Hospital. Salem and Lewandowski were the first users of this platform worldwide. The Direxion Torqueable Microcatheter is designed to facilitate selective access and delivery of diagnostic, embolic and therapeutic See full press release